Overview
This is an observational, retrospective/prospective, multicenter study designed to define, overall survival, clinical outcomes and predictive/prognostic factors of a consecutive population of mCRPC patients treated with olaparib in clinical practice.
Eligibility
Inclusion Criteria:
BRCA mutant Metastatic castration-resistant prostate cancer patients treatment with olaparib in clinical practice
Exclusion Criteria:
Olaparib treatment in a clinical trial